US 11,986,538 B2
Immunoswitch nanoparticles for reprogrammed T cell responses
Alyssa K. Kosmides, Balitmore, MD (US); and Jonathan P. Schneck, Silver Spring, MD (US)
Assigned to The Johns Hopkins University, Baltimore, MD (US)
Filed by The Johns Hopkins University, Baltimore, MD (US)
Filed on Dec. 21, 2021, as Appl. No. 17/557,886.
Application 17/557,886 is a continuation of application No. 16/327,508, abandoned, previously published as PCT/US2017/048196, filed on Aug. 23, 2017.
Claims priority of provisional application 62/515,810, filed on Jun. 6, 2017.
Claims priority of provisional application 62/378,406, filed on Aug. 23, 2016.
Prior Publication US 2022/0111069 A1, Apr. 14, 2022
Int. Cl. A61K 47/00 (2006.01); A61K 9/00 (2006.01); A61K 9/51 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61K 47/69 (2017.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01)
CPC A61K 47/6939 (2017.08) [A61K 9/0009 (2013.01); A61K 9/0019 (2013.01); A61K 9/5161 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61K 47/6849 (2017.08); A61K 47/6873 (2017.08); A61P 35/00 (2018.01); C07K 16/2827 (2013.01); C07K 16/2878 (2013.01); C12N 5/0638 (2013.01); A61K 2039/507 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01)] 18 Claims
 
1. An immunoswitch particle comprising a nanoparticle comprising:
a first agent that indirectly modulates an immunosuppressive pathway in a tumor cell or immunosuppressive molecule induced by the tumor cell in the tumor microenvironment; and
a second agent that simultaneously targets a co-stimulatory pathway or co-inhibitory pathway in a T cell,
wherein the first agent is a CD73 antagonist antibody or a functional variant thereof that is a CD73 antagonist; and the second agent is a 4-1BB agonist antibody or a functional variant thereof that is a 4-1BB agonist.